Upper gastrointestinal safety evaluation of parecoxib sodium, a new parenteral cyclooxygenase-2-specific inhibitor, compared with ketorolac, naproxen, and placebo. [electronic resource]
Producer: 20020123Description: 1422-8 p. digitalISSN:- 0149-2918
- Aged
- Analgesics, Non-Narcotic -- adverse effects
- Anti-Inflammatory Agents, Non-Steroidal -- adverse effects
- Cyclooxygenase 2
- Cyclooxygenase 2 Inhibitors
- Cyclooxygenase Inhibitors -- adverse effects
- Double-Blind Method
- Female
- Gastric Mucosa -- drug effects
- Humans
- Infusions, Parenteral
- Isoenzymes
- Isoxazoles -- adverse effects
- Ketorolac -- adverse effects
- Male
- Membrane Proteins
- Naproxen -- adverse effects
- Peptic Ulcer -- chemically induced
- Prostaglandin-Endoperoxide Synthases
No physical items for this record
Publication Type: Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.